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Sir,
Polymyxins (colistin and polymyxin B) have recently regained a
role as last-resort antibiotics for treatment of infections caused by
XDR Gram-negative bacteria.1 Consequently, the emergence and
diffusion of colistin resistance is of great concern.
Acquisition of colistin resistance is mainly associated with
chromosomal mutations.1 However, transferable resistance,
mediated by the plasmid-borne mcr-type genes (encoding phos-
phoethanolamine transferases that modify lipid A), has recently
been reported.1 mcr-1 was the first to be reported and, since its
first identification in China,2 it has been detected worldwide in
Enterobacteriaceae (mostly Escherichia coli) isolated fromanimals,
food, environments and humans.1 Themcr-1 gene has been asso-
ciated with different plasmid replicons such as IncI2, IncHI1,
IncHI2, IncP, IncFII, IncFIB and IncX4,3 and was found only rarely
to be chromosomally encoded.4
In Latin America, E. coli harbouring mcr-1 have been
described in Brazil, Ecuador, Venezuela and Argentina from
food-producing animals and human clinical samples.5–8
Moreover, a study reported intestinal colonization by mcr-1-
positive E. coli in two unrelated travellers, who had visited Peru,
Bolivia and Colombia, suggesting the presence of the gene in
those countries.9
Here we report on the first detection of an mcr-1-positive
Citrobacter braakii isolated in the Bolivian Chaco region from ready-
to-eat food.
In 2013, a pilot study was performed in the local markets of
Camiri (Cordillera Province, Santa Cruz Department) and
Villa Montes (Gran Chaco Province, Tarija Department), with
the aim of investigating the presence of antibiotic-resistant
Enterobacteriaceae in samples of ready-to-eat food. A total of 100
food samples were analysed as follows. A sliver of each sample
was incubated at 35!C in tryptic soy broth plus 2mg/L vancomycin
for 24h, and then the broth (10lL) was plated onto MacConkey
agar. Overall, 83 food specimens yielded bacterial colonies on
MacConkey agar, and these were successively pooled and stored
at#80!C pending further analysis.
Screening for the presence of the mcr-1 gene2 identified one
mcr-positive bacterial pool, obtained from a boiled potato. Plating
the bacterial pool onto MacConkey agar plus 2mg/L colistin
allowed recovery of an isolate, named CA-26, identified as
Citrobacter freundii by MALDI-TOF MS (bioMe´rieux Inc., Marcy-
l’!Etoile, France). Susceptibility testing performedby reference broth
microdilution10 and interpreted according to the EUCAST break-
points (http://www.eucast.org/clinical_breakpoints/) revealed that
CA-26 was susceptible to all tested antibiotics (Table S1, available
as Supplementary data at JACOnline)with the exception of colistin
(MIC"8mg/L).
A conjugation experiment,11 using E. coli J53 (F#met pro Azir) as
recipient and selection with colistin (2mg/L) and sodium azide
(150mg/L) yielded J53 transconjugants at a frequency of
7%10#5+2%10#5 transconjugants per recipient. Transconjugants
carried the mcr gene, as assessed by PCR, and were resistant to
colistin (MIC"4mg/L).
Genomic DNA of CA-26 was extracted using a QIAsymphony
automated station (Qiagen, Hilden, Germany) and subjected to
WGS using a HiSeq Illumina platform (Illumina, San Diego, CA,
USA). The draft genome assembly included 94 contigs, with an
estimated genome size of 5 072 546bp and an average coverage
of 80%.
Analysis of 16S rRNA, leuS, recN, rpoB, pyrG and fusA gene se-
quences12 unambiguously identified CA-26 as C. braakii. In silico
analysis of the antimicrobial resistome confirmed the presence of
a plasmid-borne mcr-1 gene and of the chromosomal blaCMY-82
(accession no. KJ207203) AmpC-type b-lactamase gene.
The sequence of the mcr-1-bearing plasmid, named pCA-26,
was assembled in two contigs and the complete sequence was
achieved using PCR and Sanger sequencing. Plasmid pCA-26 was
62 214bp long, with an average GC content of 42.7%, and be-
longed to the IncI2 lineage. Its overall structurewas similar to that
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of other IncI2 plasmids carrying mcr-1, previously described from
other areas (99% nucleotide identity over a sequence coverage
ranging from 85% to 96%; Table S2). The main differences
consisted of the presence of additional IS elements or of an
ISEcp1-blaCTX-M-55/64 resistance module in some of the other plas-
mids (Figure 1). Themcr-1-pap cassette in pCA-26 was inserted in
a conserved position (i.e. downstream of the nikB locus) compared
with other IncI2-type plasmids, and was not associated with any
flanking mobile element (e.g. ISApl1). An SNP-based phylogenetic
analysis identified pA31-12, an mcr-1- and blaCTX-M-55-carrying
plasmid from an E. coli isolated from chicken in China in 2012, as
the closest relative to pCA-26 (Table S2). The similarity of themcr-
1 genetic support to that from isolates from China suggests a pos-
sible epidemiological link between China and Bolivia, as also previ-
ously suggested.11 Nevertheless, a possible spread at the food,
environmental and human level among Latin American countries
could not be excluded. In fact, a recent report,5 showing the pres-
ence of themcr-1 gene in Brazilian livestock, dated the presence of
mcr-1 in Latin America back to 2012, suggesting that this resist-
ance determinant has been circulating in Latin America for at least
5 years.
To the best of our knowledge this is the first description of the
mcr-1 gene in C. braakii, and also the first direct report of mcr-1
from Bolivia. This finding underlines that the mcr-1 determinant
could bewidespread throughout Latin America, and further under-
scores its ability to horizontally disseminate among different
enterobacterial species.
Nucleotide sequences
The draft genome of C. braakii CA-26 and the complete sequence
of plasmid pCA-26 have been deposited under GenBank accession
numbersMTJW00000000and KY624633, respectively.
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Sir,
IMI carbapenemases, named based on their ability to hydrolyse
imipenem, are Ambler class A enzymes. blaIMI-1 was first identified
on the chromosome of two Enterobacter cloacae isolates from the
USA in 1984,1 and subsequently small numbers of IMI-positive iso-
lates have been identified in China, Finland, France, Ireland,
Norway, Singapore, Tahiti (French Polynesia) and the USA.2,3 In
contrast, IMI-2 and IMI-3 have been described as plasmid-
mediated enzymes in Enterobacter asburiae and E. cloacae, re-
spectively.4,5 Twelve IMI variants have now been identified
(https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047) and to
date the only report of an IMI carbapenemase identified outside of
the genus Enterobacter has been in a single isolate of Escherichia
coli from Spain.6 Here we report an IMI-2 carbapenemase in a
Klebsiella variicola strain isolated in theUK.
The strain was initially isolated from an intensive therapy unit
patient in 2011 from a soft tissue infection of the buttock and
referred to the Specialist Antimicrobial Chemotherapy Unit, Public
Health Wales, for investigation of carbapenem resistance. The pa-
tient had no known recent travel history. The strain was identified
as a Klebsiella pneumoniae by BD PhoenixTM (BD Diagnostics,
Oxford, UK). MICs of ertapenem, meropenem and imipenemwere
.32mg/L, with susceptibility to cefotaxime and ceftazidime (MICs
"0.25mg/L) as determined by LiofilchemVR MIC test strips (Launch
Diagnostics, Longfield, UK). Disc inhibition tests (BioConnections,
Knypersley, UK) gave positive results for class A and AmpC enzyme
activity, but the isolate was negative for KPC, OXA-48 and OXA-23
carbapenemase and plasmid-mediated AmpC genes by in-house
PCR. The isolate was subsequently referred to PHE’s Antimicrobial
Resistance and Healthcare Associated Infections (AMRHAI)
Reference Unit for further investigation, where MICs were deter-
mined against AMRHAI’s standard panel of Gram-negative antibi-
otics, which includes ertapenem, meropenem and imipenem,
using agar dilution, and interpreted using EUCAST criteria.
Identification as a K. pneumoniae was confirmed by MALDI-TOF
MS (BrukerMicroflex LT, Bruker Daltonik GmbH, Bremen, Germany).
To investigate the underlying carbapenem resistance mechan-
ism(s) the strain was used as a plasmid donor in electro-
transformation to E. coli Alpha-Select cells (Bioline, London, UK),
with transformants selected on LB agar containing 100mg/L
ampicillin onto which a 10lg ertapenem disc was placed. WGS of
the clinical isolate and transformant was performed using a HiSeq
sequencer (Illumina) and the resulting data were analysed using
an in-house bioinformatics pipeline, as previously described.7
Transformant reads were assembled into contigs using SPAdes
3.5.0 (http://cab.spbu.ru/software/spades/). Plasmid contigs were
extracted from the E. coli Alpha-Select genome by in silico subtrac-
tion and assembled; replicon typing was performed using
PlasmidFinder (https://cge.cbs.dtu.dk/services/PlasmidFinder/).
The strain was resistant to the carbapenems (MICs: ertapenem
.16mg/L, meropenem.32mg/L and imipenem.128mg/L), but
fully susceptible to the cephalosporins (MICs: cefotaxime
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